Organic Forti-Flax
On sale on the US market (according to the DSLD)
Barlean's, food supplement from the US market
Organic Forti-Flax (Barlean's), a food supplement au code-barres 705875100229, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. Doses of folates, niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Potassium: up to 120 mg a day according to the label (at most 1 serving a day), above the maximum dose of 80 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Barlean's
- Barcode
- 705875100229
- Form
- Powder
- One serving
- 4 tablespoons
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- organic Flax
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Calories | Other | 80 Calorie(s) |
| Calories from Fat | Other | 60 Calorie(s) |
| Total Fat | Fat | 6 Gram(s) |
| Saturated Fat | Fat | 0.5 Gram(s) |
| Polyunsaturated Fat | Fat | 4.5 Gram(s) |
| Monounsaturated Fat | Fat | 1 Gram(s) |
| Total Carbohydrates | Carbohydrate | 4 Gram(s) |
| Dietary Fiber | Fibre | 4 Gram(s) |
| Protein | Protein | 3 Gram(s) |
| Vitamin C | Vitamin | 0.1 mg |
| Vitamin E | Vitamin | 0.07 UI |
| Thiamine | Vitamin | 0.25 mg |
| Riboflavin | Vitamin | 0.02 mg |
| Niacin | Vitamin | 0.46 mg |
| Vitamin B6 | Vitamin | 0.07 mg |
| Folate | Vitamin | 13 µg |
| Pantothenic Acid | Vitamin | 0.15 mg |
| Calcium | Mineral | 38 mg |
| Iron | Mineral | 0.86 mg |
| Phosphorus | Mineral | 96 mg |
| Magnesium | Mineral | 59 mg |
| Zinc | Mineral | not stated |
| Copper | Mineral | 0.18 mg |
| Manganese | Mineral | 0.37 mg |
| Sodium | Mineral | 5 mg |
| Potassium | Mineral | 120 mg |
| Omega-3 Polyunsaturated Fat | ||
| Alpha-Linolenic Acid | Fatty acid | 3,420 mg |
| Omega-6 Polyunsaturated Fat | ||
| Linoleic Acid | Fatty acid | 885 mg |
| Omega-9 Monounsaturated Fat | ||
| Oleic Acid | Fatty acid | 1,100 mg |
| Amino Acids | Blend | not stated |
| Alanine | Amino acid | 139 mg |
| Arginine | Amino acid | 289 mg |
| Aspartic Acid | Amino acid | 307 mg |
| Cysteine | Amino acid | 51 mg |
| Glutamic Acid | Amino acid | 606 mg |
| Glycine | Amino acid | 187 mg |
| Histidine | Amino acid | 71 mg |
| Isoleucine | Amino acid | 134 mg |
| Leucine | Amino acid | 185 mg |
| Lysine | Amino acid | 129 mg |
| Methionine | Amino acid | 56 mg |
| Phenylalanine | Amino acid | 144 mg |
| Proline | Amino acid | 121 mg |
| Serine | Amino acid | 145 mg |
| Threonine | Amino acid | 115 mg |
| Tryptophan | Amino acid | 45 mg |
| Tyrosine | Amino acid | 74 mg |
| Valine | Amino acid | 161 mg |
| Phyto-Nutrients | Blend | not stated |
| Lignans | Other substance | 110 mg |
| Phenolic Acids | Other substance | 100 mg |
| Flavonoids | Other substance | 5 mg |
| Phytic Acid | Other substance | 320 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Organic Forti-Flax
Entered into DSLD on 21 November 2016. Withdrawn from the US market on 23 August 2016 (according to the DSLD).- Active ingredient added : Trans Fat (0 Gram(s))
- Different quantity per serving : Glutamic Acid: 605 mg in this version; 606 mg on the displayed label
- Different quantity per serving : Linoleic Acid: 185 mg in this version; 885 mg on the displayed label
- Different quantity per serving : Magnesium: 50 mg in this version; 59 mg on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Arginine
Read the warning, when it applies and the studies cited
L-ARGININE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.
Condition of application: Improvement in exercise capacity in individuals with stable CVD.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician if your symptoms worsen.
Applies to products providing more than 0.42 g of L-Arginine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).
Sources cited by Health Canada (7)
- Bednarz B, Wolk R, Chamiec T, Herbaczyńska-Cedro K, Winek D, Ceremużyński L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. International Journal of Cardiology 2000;75(2-3):205-210. PubMed Randomised trial
- Ceremużyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. The American Journal of Cardiology 1997;80(3):331-333. PubMed Randomised trial
- Doutreleau S, Rouyer O, Di Marco P, Lonsdorfer E, Richard R, Piquard F, Geny B. L-Arginine supplementation improves exercise capacity after a heart transplant. American Journal of Clinical Nutrition. 2010. Doi: 10.3945/ajcn.2009.27881. DOI
- Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J., Beny B. Chronic L-Arginine Supplementation Enhances Endurance Exercise Tolerance in Heart Failure Patients. International Journal of Sports Medicine 2006;27(7):567-572. PubMed
- Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2001;163(4):887-891. PubMed Randomised trial
- Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral –arginine in patients with heart failure. Circulation 1996;93(12):2135-2141. PubMed Randomised trial
- Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).
Sources cited by Health Canada (4)
- Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. Journal of the American College of Cardiology 1995;26(4):1054-1061. PubMed Randomised trial
- Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: Its potential role in nitric oxide generation. American College of Nutrition 2002;21(5):422-427. PubMed Clinical trial
- Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. Journal of the American College of Cardiology 2002;39(7):1199-1203. PubMed Randomised trial
- Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. American Journal of Hypertension 2000;13(5):547-551. PubMed Randomised trial
Contraindications
Applies to products providing more than 9 g of L-Arginine, per day.
Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).
Sources cited by Health Canada (3)
- Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62(5):421-427. PubMed Randomised trial
- Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
- Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin Cardiol. 2009;32(11):649-652. PubMed Meta-analysis
Known adverse reactions
Applies to products providing more than 9 g of L-Arginine, per day.
When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).
Sources cited by Health Canada (4)
- Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine endothelium-dependent dilation in hypercholesterolemic young adults. Journal of Clinical Investigation 1996;97(8):1989-1994. PubMed Randomised trial
- Evans WR, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. Journal of Nutritional Biochemistry 2004;15(9):534-539. PubMed
- Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. The Journal of Nutrition 2007;137(6 Suppl 2):1693S-1701S. PubMed Review article
- IOM 2005: Institute of Medicine. Panel on Dietary Reference Intakes for Electrolytes and Water, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington (DC): National Academies Press; 2005.
- Lysine
Read the warning, when it applies and the studies cited
LYSINE
Route of administration: Oral
Cautions and warnings
Applies to products providing more than 300 mg of lysine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Goldman and Ausiello 2004).
Sources cited by Health Canada (1)
- Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.
- Tyrosine
Read the warning, when it applies and the studies cited
L-TYROSINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Barlean's
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Organic Forti-Flax (Barlean's): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/705875100229-organic-forti-flax-barlean-s, updated 25 January 2017.